Stevan Milhoan, MD
Internal Medicine · Vienna, WVNPI 1780661652
Payments from drug & device makers
Across 196 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$614
- Novo Nordisk$269
- Kowa Pharmaceuticals America, Inc.$242
- Amgen$234
- GSK$206
- Pfizer$192
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,800100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $614 |
| Novo Nordisk | 21 | $269 |
| Kowa Pharmaceuticals America, Inc. | 22 | $242 |
| Amgen | 16 | $234 |
| GSK | 21 | $206 |
| Pfizer | 15 | $192 |
| Lilly USA, LLC | 15 | $191 |
| CSL Behring | 8 | $130 |
| Amarin Pharma, Inc. | 7 | $104 |
| AbbVie | 6 | $92 |
| Sanofi-aventis U.S. LLC | 5 | $88 |
| Arbor Pharmaceuticals, Inc. | 6 | $81 |
| Shire North American Group Inc | 4 | $70 |
| Novartis | 3 | $40 |
| Merck | 3 | $40 |
| Ironshore Pharmaceuticals Inc. | 2 | $39 |
| Neos Therapeutics, LP | 2 | $34 |
| Phadia US Inc. | 2 | $28 |
| Astellas Pharma US Inc | 1 | $23 |
| Smith+Nephew | 1 | $21 |
| Corium, LLC | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$2,806 in reported general payments places this provider in the 80th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 28 | $33,491 |
| OzempicSemaglutide | 20 | $32,950 |
| EliquisApixaban | 37 | $20,950 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $20,059 |
| JardianceEmpagliflozin | 19 | $17,994 |
| TrulicityDulaglutide | 18 | $16,816 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $12,533 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $11,684 |
| PremproEstrogen,con/M-Progest Acet | 13 | $3,091 |
| Atorvastatin Calcium | 292 | $2,240 |
| Pantoprazole Sodium | 181 | $1,795 |
| Dofetilide | 11 | $1,588 |
| Famotidine | 112 | $1,561 |
| Colestipol Hcl | 14 | $1,472 |
| Gabapentin | 114 | $1,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $40 | $33,49128 claims |
| Novo NordiskOzempic | $269 | $32,95020 claims |
| PfizerEliquis, Prempro | $192 | $24,04150 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $88 | $20,05912 claims |
| Boehringer IngelheimJardiance | $15 | $17,99419 claims |
| Lilly USA, LLCTrulicity | $191 | $16,81618 claims |
| GSKTrelegy Ellipta | $206 | $11,68419 claims |
| AbbVieSynthroid | $92 | $68712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Vienna
- Rabina Malik-HamiraniVienna$6K
- Ward PaineMorgantown$5.1M
- William ChapmanCharleston$1.7M
- Mustafa AwiliHuntington$906K
- David PickeringParkersburg$694K
- Laura DavissonMorgantown$118K
- Michael BrumageClendenin$87K
- Govind PatelFairmont$59K
- Lynn SmithLewisburg$31K
- Bisher MustafaHuntington$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.